| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab plus nab-paclitaxel | atezolizumab plus paclitaxel | pembrolizumab plus SoC |
mBC - Triple negative (TNBC) - 1st Line (L1) 1 | | | |
mBC - TNBC - L1 - all population 7 | | | |
mBC - TNBC - L1 - PDL1 positive 4 | | | |